Special Issue

Topic: Clinical Use of Circulating Nucleic Acids in Bodily Fluids: Noninvasive Prenatal Testing, Oncology, Transplant Monitoring and Beyond
A Special Issue of Extracellular Vesicles and Circulating Nucleic Acids
ISSN 2767-6641 (Online)
Submission deadline: 1 May 2022
Guest Editor(s)
Erik Sistermans
Professor, Department of Clinical Genetics, Amsterdam University Medical Center, Amsterdam, the Netherlands.
Special Issue Introduction
The discovery of circulating cell-free fetal DNA in maternal plasma has made a paradigm shift in noninvasive prenatal testing (NIPT), rapidly being translated into clinical practices worldwide, for example, cell-free DNA(cfDNA) based fetal chromosomal aneuploidy detection and diagnosis of monogenic diseases. Recently, many efforts have been made in expanding the success of cfDNA-based NIPT to different clinical scenarios, such as oncology and organ transplantation. CfDNA is illustrated to be non-randomly fragmented and released from multiple tissues within the body. Genetics, epigenetics, and fragmentomics of cfDNA open up many possibilities for developing novel diagnostic tools. For instance, the use of genetics of cfDNA allows for noninvasive prenatal testing for signal gene disorders such as cystic fibrosis, alpha- and beta-thalassemias, sickle cell anemia, fragile X syndrome, etc. The use of epigenetics of cfDNA (e.g., DNA methylation) is an important means for deciphering the tissues of origin of cfDNA. The fragmentomics of cfDNA, such as fragment sizes, endpoints, end motifs, jagged ends, and nucleosome profiles, is an emergent area for clinical biomarker development.
This Special Issue aims to cover cfDNA-related research articles, reviews, and perspectives, including but not limited to the topics highlighted below:
● Noninvasive prenatal testing;
● Cancer detection and monitoring;
● Organ transplant monitoring;
● Organ damage assessment (e.g., trauma, and autoimmune diseases).
This Special Issue aims to cover cfDNA-related research articles, reviews, and perspectives, including but not limited to the topics highlighted below:
● Noninvasive prenatal testing;
● Cancer detection and monitoring;
● Organ transplant monitoring;
● Organ damage assessment (e.g., trauma, and autoimmune diseases).
Submission Deadline
1 May 2022
Submission Information
For Author Instructions, please refer to https://oaepublish.com/evcna/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=evcna&SpecialIssueId=803
Submission Deadline: 1 May 2022
Contacts: Margie Ma, Managing Editor, margie@oaepublish.com
Published Articles
Open Access Review
Non-invasive prenatal diagnosis (NIPD): current and emerging technologies
This article belongs to the Special Issue Clinical Use of Circulating Nucleic Acids in Bodily Fluids: Noninvasive Prenatal Testing, Oncology, Transplant Monitoring and Beyond
Extracell Vesicles Circ Nucleic Acids 2023;4:3-26.
Available online: 21 Feb 2023
Open Access Review

Emerging frontiers of cell-free DNA fragmentomics
This article belongs to the Special Issue Clinical Use of Circulating Nucleic Acids in Bodily Fluids: Noninvasive Prenatal Testing, Oncology, Transplant Monitoring and Beyond
Extracell Vesicles Circ Nucleic Acids 2022;3:380-92.
Available online: 20 Dec 2022
Open Access Review

Towards responsible ctDNA-based multi-cancer screening: a preliminary exploration and discussion of ethically relevant aspects
This article belongs to the Special Issue Clinical Use of Circulating Nucleic Acids in Bodily Fluids: Noninvasive Prenatal Testing, Oncology, Transplant Monitoring and Beyond
Extracell Vesicles Circ Nucleic Acids 2022;3:235-43.
Available online: 15 Aug 2022
Open Access Review
Expanded knowledge of cell-free DNA biology: potential to broaden the clinical utility
This article belongs to the Special Issue Clinical Use of Circulating Nucleic Acids in Bodily Fluids: Noninvasive Prenatal Testing, Oncology, Transplant Monitoring and Beyond
Extracell Vesicles Circ Nucleic Acids 2022;3:216-34.
Available online: 9 Aug 2022
Open Access Review
Cell-free DNA as a biomarker in cancer
This article belongs to the Special Issue Clinical Use of Circulating Nucleic Acids in Bodily Fluids: Noninvasive Prenatal Testing, Oncology, Transplant Monitoring and Beyond
Extracell Vesicles Circ Nucleic Acids 2022;3:195-215.
Available online: 1 Aug 2022